Mereo BioPharma
MREO
72 hedge funds and large institutions have $146M invested in Mereo BioPharma in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
14% more funds holding
Funds holding: 63 → 72 (+9)
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
2.57% less ownership
Funds ownership: 16.24% → 13.67% (-2.6%)
31% less capital invested
Capital invested by funds: $212M → $146M (-$66.5M)
51% less call options, than puts
Call options by funds: $37K | Put options by funds: $75K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.23M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.51M |
| 3 |
Goldman Sachs
New York
|
+$1.42M |
| 4 |
CC
Clearline Capital
New York
|
+$1.37M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$34.5M |
| 2 |
ACM
Altium Capital Management
New York
|
-$3.02M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.94M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.81M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$1.57M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
76
Valeo Financial Advisors
Carmel,
Indiana
| – | -$54K | -22,506 | Closed |
|
77
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$18K | -7,500 | Closed |
|
78
Wells Fargo
San Francisco,
California
| – | -$6K | -3,000 | -93% |
|
79
US Bancorp
Minneapolis,
Minnesota
| – | +$26 | +13 | New |
|
MREO Hedge Fund Activity: Q4 2021 in Review
72 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2021, worth a combined $146M — down 31% from $212M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MREO positions and 10 closed out — a net gain of 10 holders — while 18 added to existing stakes and 16 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $7.23M. The largest seller was OrbiMed, exiting entirely with an estimated $34.5M sold.
- 72 institutional investors held Mereo BioPharma (MREO) as of Q4 2021, up from 63 in Q3 2021.
- Funds reported $146M of Mereo BioPharma stock for Q4 2021, down 31% quarter-over-quarter.
- 20 funds opened new Mereo BioPharma positions in Q4 2021 and 10 closed out, a net change of +10 holders.
- The largest Mereo BioPharma buyer in Q4 2021 was Rubric Capital Management (New York), an estimated $7.23M added.
- The largest Mereo BioPharma seller in Q4 2021 was OrbiMed, an estimated $34.5M sold.
Based on aggregated 13F filings for Q4 2021.